Literature DB >> 1834745

Inhibition of human IgE production via Fc epsilon R-II stimulation results from a decrease in the mRNA for secreted but not membrane epsilon H chains.

A Saxon1, M Kurbe-Leamer, K Behle, E E Max, K Zhang.   

Abstract

We have previously shown, using IgE-anti-IgE immune complexes or mAb directed against CD23, that ongoing production of secreted IgE from the human plasma cell line AF-10 can be inhibited via the low affinity FcR for IgE (CD23). Changes occurring in the various forms of epsilon messenger RNA (epsilon mRNA) during this suppression were investigated. mRNA levels of lambda L chain were also assessed as well as beta-actin controls. Changes in membrane IgE and secreted IgE and lambda protein were simultaneously measured. Using a genomic probe corresponding to the human epsilon C region domains, three sets of epsilon-mRNA bands were identified (2.1, 3.0, and 3.8 kb). Only the largest of these (3.8 kb) contained the full epsilon membrane sequence and coded for true membrane epsilon protein. The 2.1-kb species of epsilon-mRNA contained no membrane sequence and coded for classical secreted epsilon protein. The intermediate epsilon-mRNA species (3.0 kb) was shown to contain membrane sequence but did not contain the full epsilon membrane sequence. The product of this mRNA would, in fact, function as a secreted protein. When IgE production by AF-10 cells was suppressed via Fc epsilon R-II, there was a 50% fall in the steady state levels of both forms of mRNA (2.1 and 3.0 kb) that code for secreted epsilon protein. Similarly, there was a fall in lambda-mRNA corresponding to the observed decrease in free lambda secretion. In marked contrast, levels of both membrane IgE protein and mRNA coding for membrane epsilon were unaltered on the suppressed AF-10 cells. These data suggest that inhibition of IgE production via Fc epsilon R-II is related to a fall in mRNA for secreted proteins (epsilon and lambda) and probably reflects a post-transcriptional mechanism effecting mRNA for secreted vs membrane protein mRNA.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834745

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Regulation of nuclear poly(A) addition controls the expression of immunoglobulin M secretory mRNA.

Authors:  C Phillips; S Jung; S I Gunderson
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

2.  Endocytosis and recycling of the complex between CD23 and HLA-DR in human B cells.

Authors:  S N Karagiannis; J K Warrack; K H Jennings; P R Murdock; G Christie; K Moulder; B J Sutton; H J Gould
Journal:  Immunology       Date:  2001-07       Impact factor: 7.397

3.  Characterization of the human immunoglobulin epsilon mRNAs and their polyadenylation sites.

Authors:  F D Batista; D G Efremov; T Tkach; O R Burrone
Journal:  Nucleic Acids Res       Date:  1995-12-11       Impact factor: 16.971

4.  Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo.

Authors:  M Haak-Frendscho; K Robbins; R Lyon; R Shields; J Hooley; M Schoenhoff; P Jardieu
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

Review 5.  Fifty years later: Emerging functions of IgE antibodies in host defense, immune regulation, and allergic diseases.

Authors:  Hans C Oettgen
Journal:  J Allergy Clin Immunol       Date:  2016-06       Impact factor: 10.793

6.  Two unusual forms of human immunoglobulin E encoded by alternative RNA splicing of epsilon heavy chain membrane exons.

Authors:  K Zhang; A Saxon; E E Max
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

Review 7.  IgE and IgG Antibodies as Regulators of Mast Cell and Basophil Functions in Food Allergy.

Authors:  Cynthia Kanagaratham; Yasmeen S El Ansari; Owen L Lewis; Hans C Oettgen
Journal:  Front Immunol       Date:  2020-12-11       Impact factor: 7.561

8.  IgE-tailpiece associates with α-1-antitrypsin (A1AT) to protect IgE from proteolysis without compromising its ability to interact with FcεRI.

Authors:  Phyllis M Quinn; David W Dunne; Shona C Moore; Richard J Pleass
Journal:  Sci Rep       Date:  2016-02-04       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.